Cargando…

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction

Background: The implications of mineralocorticoid receptor antagonists, including the newly introduced esaxerenone, on cardiac reverse remodeling in patients with heart failure with preserved ejection fraction (HFpEF) remain uncertain. Methods and Results: We included patients with HFpEF who receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imamura, Teruhiko, Oshima, Akira, Narang, Nikhil, Kinugawa, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2021
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578130/ https://www.ncbi.nlm.nih.gov/pubmed/34805606 http://dx.doi.org/10.1253/circrep.CR-21-0115

Ejemplares similares

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction
por: Kagami, Kazuki, et al.
Publicado: (2023)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Chronotype of Lung Fluid Levels in Patients with Chronic Heart Failure
por: Ueno, Yohei, et al.
Publicado: (2022)

Implications of Doppler Echocardiography-guided Heart Rate Modulation Using Ivabradine
por: Hori, Masakazu, et al.
Publicado: (2021)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2016)

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Prognostic Implication of Small Dense LDL-Cholesterol Levels following Acute Coronary Syndrome
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Prognostic Implications of a Modified Seattle Heart Failure Model Score Following Transcatheter Aortic Valve Replacement
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study
por: Iwahana, Togo, et al.
Publicado: (2021)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials
por: Chen, Yanmei, et al.
Publicado: (2015)

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
por: Rahman, Asadur, et al.
Publicado: (2021)

Correction: Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Publicado: (2023)

Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Pressure Ramp Testing for Optimization of End-Expiratory Pressure Settings in Adaptive Servo-Ventilation Therapy
por: Hori, Masakazu, et al.
Publicado: (2021)

Lung Fluid Volume during Cardiopulmonary Exercise Testing
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
por: Izumida, Toshihide, et al.
Publicado: (2022)

Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure
por: Hori, Masakazu, et al.
Publicado: (2020)

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review
por: Pandey, Ambarish, et al.
Publicado: (2015)

Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Kapelios, Chris J., et al.
Publicado: (2019)

SUN-176 A Case of Aldosterone-Producing Adenoma with Preoperative Use of a Novel Mineralocorticoid Receptor Antagonist Esaxerenone
por: Yamanami, Hiroaki
Publicado: (2020)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Inflammatory Pathways and Their Implications in Heart Failure With Preserved Ejection Fraction
por: Segar, Matthew W., et al.
Publicado: (2023)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0mmt0lntvrpuf86kmm416dp0v9